By Matt Grossman

Biogen Inc.'s aducanumab for Alzheimer's disease received a negative trend vote on its marketing-authorization application as part of the drug's review process by Europe's Committee for Medicinal Products for Human Use, Biogen said Wednesday.

The vote precedes the expected adoption of the CHMP's formal opinion on the drug next month.

"While we are disappointed with the trend vote, we strongly believe in the strength of our data and that aducanumab has the potential to make a positive and meaningful difference," Biogen interim research head Dr. Priya Singha said.

The medication, which goes by brand name Aduhelm, was approved earlier this year to treat Alzheimer's disease in the U.S.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

11-17-21 0804ET